Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder
Sponsor
Pharmacology Research Institute (Other)
Overall Status
Completed
CT.gov ID
NCT00290914
Collaborator
(none)
Study Details
Study Description
Brief Summary
The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Male or female patients 18-65 years of age, inclusive.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pharmacology Research Institute
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00290914
Other Study ID Numbers:
- PRI #608
First Posted:
Feb 13, 2006
Last Update Posted:
May 9, 2012
Last Verified:
May 1, 2012
Additional relevant MeSH terms: